Gene · 51455
REV1: REV1 DNA directed polymerase
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. REV1: REV1 DNA directed polymerase. Genes, record 51455. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/51455
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| Q9UBZ9 | Translesion synthesis protein REV1 | 1,251 | 17 | Ensembl, GeneID, HGNC |
Source UniProt
Patents25
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| EP 4641201 A2 | 2025-10-29 | 1294 | Q9UBZ9 | Espacenet |
| US 12435331 B2 | 2025-10-07 | 64 | Q9UBZ9 | Espacenet |
| JP 2025517969 A | 2025-06-12 | 1294 | Q9UBZ9 | Espacenet |
| JP 2024533316 A | 2024-09-12 | 4428 | Q9UBZ9 | Espacenet |
| JP 2024123008 A | 2024-09-10 | 8191 | Q9UBZ9 | Espacenet |
| EP 4399291 A2 | 2024-07-17 | 4428 | Q9UBZ9 | Espacenet |
| JP 2023113627 A | 2023-08-16 | 64 | Q9UBZ9 | Espacenet |
| US 11542496 B2 | 2023-01-03 | 64 | Q9UBZ9 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 73082 | Q9UBZ9 | Espacenet |
| JP 2022524081 A | 2022-04-27 | 176053 | Q9UBZ9 | Espacenet |
1 to 10 of 25
See all 25 patentsDrugs0
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
None in this release.
Trials0
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
None in this release.
NIH grants1,230
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | REV1 papers | Newest fiscal year |
|---|---|---|---|
| P30CA086862 | Cancer Center Support Grant | 14 | 2025 |
| ZIAHD001500 | DNA Replication, Repair, and Mutagenesis In Eukaryotic And Prokaryotic Cells | 14 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 12 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 11 | 2025 |
| P30ES010126 | UNC Center for Environmental Health and Susceptibility | 11 | 2025 |
| P01CA092584 | Structural Cell Biology of DNA Repair Machines | 9 | 2025 |
| P30CA068485 | Cancer Center Support Grant | 9 | 2025 |
| R01HL052725 | Molecular Pathogenesis of Fanconi Anemia | 9 | 2025 |
| P30CA016086 | Cancer Center Support Grant | 5 | 2025 |
| R01CA237263 | DNA replication stress in cancer | 5 | 2025 |
1 to 10 of 1,230Source NIH's project files
See all 1,230 nih grantsPapers1,571
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Inhibition of Translesion DNA Synthesis Sensitizes BRCA-Deficient Ovarian Cancer to PARP Inhibitors. | Cancer Res | 2026 | 42804161 | PubTator, text mining | PubMed |
| Structural insight into human Y-family polymerases and mechanistic basis of translesion synthesis of key DNA damages. | Mutat Res Rev Mutat Res | 2026 | 42767445 | PubTator, text mining | PubMed |
| The Oligomeric State of Rad6-Rad18 and Its Interactions with Translesion Synthesis Proteins. | Biomolecules | 2026 | 42650838 | PubTator, text mining | PubMed |
| Targeting MAD2L2-dependent translesion synthesis impairs DNA damage tolerance and enhances cellular response to cisplatin. | Front Cell Dev Biol | 2026 | 42591613 | PubTator, text mining | PubMed |
| Human REV1 interacts with DHX36 to promote replication and tolerance of G-quadruplex DNA. | Nucleic Acids Res | 2026 | 42258547 | PubTator, text mining | PubMed |
| A sibling study of variation in parental mutation rates. | bioRxiv | 2026 | 42182135 | PubTator, text mining | PubMed |
| Targeted tumor starvation strategy augments radiosensitivity and enhances radioactive iodine-mediated tumor immunotherapy. | Acta Pharmacol Sin | 2026 | 41781702 | PubTator, text mining | PubMed |
| Virtual Reality in Chronic Conditions: An Umbrella Review. | Nurs Rep | 2026 | 41745882 | PubTator, text mining | PubMed |
| SEC11A identified as a critical host factor for HMPV through virus-induced alternative splicing. | Biosaf Health | 2026 | 41743027 | PubTator, text mining | PubMed |
| Advancing inducible gene-inactivation systems to explore synthetic lethality. | NAR Cancer | 2026 | 41736896 | PubTator, text mining | PubMed |
1 to 10 of 1,571
See all 1,571 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/51455
GET https://conductscience.org/api/genes/v1/51455/patents?page=2